AEGiS-CATIE: TreatmentUpdate: Indinavir combinations

TreatmentUpdate: Indinavir combinations

TreatmentUpdate 76. 9(2): 6-7; March, 1997
Sean Hosein

This article is based on information presented at the 4th Conference on Retroviruses and Opportunistic Infections in Washington, DC, January 22-26, 1997.

Study details

Doctors enrolled 320 subjects who had used AZT for at least 6 months but who had never taken protease inhibitors or 3TC. At the start of the study 50% of subjects had a CD4+ count of 15 cells and a viral load of 91,210 copies. Subjects received indinavir 2.4 g/day or a combination of AZT/3TC or all three drugs (triple therapy) at standard doses.

Results

By the 6th month of the study, subjects on ?triple therapy? had the greatest decrease in viral load. Indeed, 65% of them had their viral load fall to below 500 copies. Subjects on triple therapy had their CD4+ count rise by about 86 cells, also at the 6th month.

Indinavir with nevirapine and 3TC

Doctors in Vancouver recruited 21 subjects (2 female, 19 male) who had less than 51 CD4+ cells and had extensively used anti-HIV drugs and experienced serious toxicity with them. Subjects received indinavir 2.4 g/day, nevirapine 200 mg/day for the first 2 weeks, after which it was given at a dose of 400 mg/day; and 3TC 300 mg/day.

Results

By the 8th week, 10 subjects who had entered the study with a viral load of 190,546 copies, had their viral load fall to 851 copies. The abstract did not have information on CD4+ cell counts. It will be interesting to see if this decrease in viral load continues and is linked with beneficial effects. Although no subject developed kidney stones, two had intestinal problems because of indinavir and had to leave the study. At least one person had a skin rash from nevirapine.

REFERENCES:

1. Hirsch M, Meibohm A, Rawlins S, et al. Indinavir in combination with zidovudine (ZDV) and lamivudine in AZT-experienced patients with CD4+ cell counts - 50 cells/mm3. Oral presentation LB7.

2. Harris M, Durakovic C, Conway B, et al. A pilot study of indinavir, nevirapine and 3TC in patients with advanced disease. Abstract 234.

970320
CATE7608

ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users l This article first appeard in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1997 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca

Disclaimer: The editors have taken all such care as they consider reasonable in preparing this database, but they cannot be held responsible for any inaccuracies or mis-statements of fact contained herein. Inclusion in this database of any information on any treatment, therapy, or clinical trial in no way represents an endorsement of that treatment, therapy, or trial by ÆGiS or any of its sponsors. This data should always be used in conjunction with professional medical advice.
©1997. ÆGiS.